Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption
Rev. Soc. Bras. Med. Trop
; Rev. Soc. Bras. Med. Trop;53: e20180498, 2020. tab
Article
em En
| LILACS
| ID: biblio-1057281
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance.METHODS:
Data were obtained from ICUs between 2010 and 2013.RESULTS:
P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B.CONCLUSIONS:
Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Pseudomonas aeruginosa
/
Infecções por Pseudomonas
/
Infecção Hospitalar
Tipo de estudo:
Prevalence_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article